Takeda Pharmaceutical Company Limited (TAK)
TAK trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-03-31, https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/0001395064-26-000177-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-03-31. Converted from JPY at 159.9982 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | TAK on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Japan |
| IPO year | 2018 |
| SEC CIK | 0001395064 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $28.2B |
| Net income | -$952.4M |
| Operating income | $38.9M |
| Net margin | -3.4% |
| Operating margin | 0.1% |
| Revenue growth | -1.7% |
| Cash | $3.7B |
| Total assets | $96.9B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.4× |
Reported in JPY; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-06-17 |
| Cash and burn | 595.1B JPY cash; operating cash flow 260.4B JPY a quarter. | Report 2026-03-31 |
| Shares outstanding | 3,159,673,660 (2026-03-31). the newest SEC cover-page count is from 2026-03-31; shares issued since then are not in these figures. | Cover page 2026-03-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG AZSA LLC, Tokyo, Japan | PCAOB Form AP 2026-07-22 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $13.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-03-31 | 4.51T JPY | -152.4B JPY | 1.04T JPY | 595.1B JPY | 4.88T JPY | 4.51T JPY | 20-F 2026-06-17 |
| FY 2025 2025-03-31 | 4.58T JPY | 107.9B JPY | 1.06T JPY | 385.1B JPY | 4.52T JPY | 4.58T JPY | 20-F 2025-06-25 |
| FY 2024 2024-03-31 | 4.26T JPY | 144.1B JPY | 716.3B JPY | 457.8B JPY | 4.84T JPY | 4.26T JPY | 20-F 2025-06-25 |
| FY 2023 2023-03-31 | 4.03T JPY | 317.0B JPY | 977.2B JPY | 533.5B JPY | 4.38T JPY | 4.03T JPY | 20-F 2025-06-25 |
| FY 2022 2022-03-31 | 3.57T JPY | 230.1B JPY | 1.12T JPY | 849.7B JPY | 4.35T JPY | 3.57T JPY | 20-F 2024-06-26 |
| FY 2021 2021-03-31 | 3.20T JPY | 376.0B JPY | 1.01T JPY | 966.2B JPY | 4.64T JPY | 3.20T JPY | 20-F 2023-06-28 |
| FY 2020 2020-03-31 | 3.29T JPY | 44.2B JPY | 669.8B JPY | 637.6B JPY | 5.09T JPY | 3.29T JPY | 20-F 2022-06-29 |
| FY 2019 2019-03-31 | 2.10T JPY | 135.2B JPY | 328.5B JPY | 702.1B JPY | 5.75T JPY | 2.10T JPY | 20-F 2021-06-29 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in JPY.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2025-06-27 |
| Latest annual report | 20-F | 2026-06-17 |
| Latest quarterly / interim | 6-K | 2026-10-29 |
Source: SEC EDGAR submissions feed, 710 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.0% |
| 1 month | +15.7% |
| 3 months | +23.2% |
| Year to date | +37.5% |
| 1 year | +50.5% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TEVA | Teva Pharmaceutical Industries Limited | $42.57 | -4.34% | $49.7B |
| REGN | Regeneron Pharmaceuticals Inc. | $952.40 | -0.32% | $98.5B |
| ONC | BeOne Medicines Ltd. | $411.29 | -1.26% | $47.0B |
| GSK | GSK plc | $50.41 | -0.08% | $102.0B |
| SNY | Sanofi ADS | $48.39 | +0.04% | $118.0B |
| RPRX | Royalty Pharma plc Class A Ordinary Shares | $68.53 | -1.13% | $39.3B |
| BMY | Bristol-Myers Squibb Company | $62.93 | -0.79% | $128.6B |
| ZTS | Zoetis Inc. | $84.39 | +0.68% | $34.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier